Black Diamond Therapeutics price target lowered to $15 from $16 at Stifel

Stifel lowered the firm’s price target on Black Diamond Therapeutics (BDTX) to $15 from $16 and keeps a Buy rating on the shares. The firm updated its model for the quarter, including the cash guidance, and made adjustments to near- to mid-term expense assumptions and the commercialization timeline given the prioritization of the first-line opportunity, the analyst tells investors.